Shanghai, China and Rockville, MD (Press Release) – I-Mab (NASDAQ: IMAB), a clin­i­cal stage bio­pharma­ceu­tical com­pany com­mit­ted to the discovery, de­vel­op­ment and com­mer­cial­iza­tion of novel or highly dif­fer­en­ti­ated biologics to treat dis­eases with sig­nif­i­cant unmet med­i­cal needs, and MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR), to­day jointly an­nounced that the first patient has been dosed in a phase 3 clin­i­cal study in main­land China to eval­u­ate MorphoSys’ inves­ti­ga­tional human CD38 anti­body TJ202 / MOR202 in com­bi­na­tion with lena­lido­mide plus dexa­meth­a­sone in patients with re­lapsed or re­frac­tory multiple myeloma (r/r …

Shanghai, China (Press Release) – I-Mab Bio­pharma­ ("I-Mab"), a global bio­pharma­ceu­tical com­pany based in China and the United States and focused on the discovery and devel­op­ment of novel or highly dif­fer­en­ti­ated biologics in immuno-oncology and auto­immune dis­eases today announced the dosing of the first patient in mainland China in its reg­is­tra­tional study eval­u­ating its human CD38 anti­body (TJ202/MOR202) in patients with re­lapsed or re­frac­tory multiple myeloma (MM).

I-Mab ini­ti­ated two reg­is­tra­tional trials with TJ202 / MOR202 in re­lapsed or re­frac­tory MM in Taiwan in early 2019 and ex­panded these trials into mainland China in …

Planegg / Munich, Germany, and Shanghai, China (Press Release) – MorphoSys AG (FSE:MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ:MOR) and I-Mab Bio­pharma­ (I-Mab) announced today that I-Mab has received Inves­ti­ga­tional New Drug (IND) clear­ances from the National Medical Products Admin­istra­tion (NMPA) of China to ex­pand the ongoing phase 2 and 3 clin­i­cal trials of MOR202 / TJ202, MorphoSys's human mono­clonal anti-CD38 anti­body for the treat­ment of multiple myeloma (MM), also to mainland China. I-Mab, a China-based clin­i­cal stage bio­pharma­ceu­tical com­pany exclusively focused on the discovery and devel­op­ment of novel or highly dif­fer­en­ti­ated …

Shanghai, China (Press Release) – I-Mab Bio­pharma­ ("I-Mab"), a China and U.S.-based clin­i­cal stage bio­pharma­ceu­tical com­pany exclusively focused on the discovery and devel­op­ment of novel or highly dif­fer­en­ti­ated biologics in immuno-oncology and auto­immune dis­eases and German biopharma com­pany MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX;Nasdaq: MOR), today announced that I-Mab has received Inves­ti­ga­tional New Drug (IND) clear­ances from the National Medical Products Admin­istra­tion (NMPA) of China to ex­pand the ongoing phase II and III clin­i­cal trials of TJ202 / MOR202, MorphoSys's human mono­clonal anti-CD38 anti­body for the treat­ment of multiple …

Shanghai, China and Munich, Germany (Press Release) – I-Mab Bio­pharma (I-Mab), a China-based clin­i­cal stage bio­pharma­ceu­tical com­pany ex­clu­sively focused on the devel­op­ment of inno­va­tive biologics in immuno-oncology and auto­immune dis­eases, and MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX;NASDAQ: MOR), an­nounced to­day that the first patient has been dosed in a phase 3 ran­dom­ized and multi-center clin­i­cal study in Taiwan to eval­u­ate MorphoSys's inves­ti­ga­tional human CD38 anti­body TJ202 / MOR202 in com­bi­na­tion with lena­lido­mide in patients with re­lapsed or re­frac­tory multiple myeloma. I-Mab has the ex­clu­sive rights for devel­op­ment and com­mer­cial­iza­tion of TJ202 / …

Shanghai, China (Press Release) – I-Mab Bio­pharma (I-Mab), a China-based clin­i­cal stage bio­pharma­ceu­tical com­pany ex­clu­sively focused on the devel­op­ment of inno­va­tive biologics in immuno-oncology and auto­immune dis­eases, and German biopharma com­pany MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX;NASDAQ: MOR), to­day an­nounced that the first patient dosing (FPD) has been achieved in a phase 2 multi-center clin­i­cal study in Taiwan to eval­u­ate an inves­ti­ga­tional human CD38 anti­body TJ202 / MOR202 in patients with re­lapsed or re­frac­tory multiple myeloma. TJ202 / MOR202 is an anti­body devel­oped by MorphoSys AG. I-Mab owns the ex­clu­sive …

Shanghai, China (Press Release) – On August 8, 2018 Beijing time I-Mab Bio­pharma ("I-Mab"), a Shanghai-based bio­tech com­pany focused on inno­va­tive biologics in on­col­ogy and auto­immune dis­ease, and German biopharma com­pany MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX;NASDAQ: MOR) an­nounced to­day that I-Mab has Submitted an inves­ti­ga­tional new drug (IND) appli­ca­tion to China National Drug Admin­istra­tion (CNDA) for TJ202 / MOR202, a human mono­clonal anti­body directed against CD38 for the treat­ment of multiple myeloma.

Multiple myeloma is the sec­ond most common blood cancer world­wide. The patient number has gradually in­­creased in China in …